IMRN

Immuron Limited

2.42 USD
+0.13 (+5.45%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Immuron Limited stock is up 8.04% since 30 days ago. The next earnings date is Jul 26, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 7 July’s closed higher than June.

About Immuron Limited

Immuron Limited researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials.